CAMBRIDGE, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Danforth Advisors, specialists in accounting, finance support and strategy for life science companies, today announced the appointment of G. Hamilton Mehlman to the newly-created role of Chief Operating Officer. Mr. Mehlman will direct Danforth’s operational scale-up and strategy, including geographic expansion of the firm’s services beyond its Boston-area roots and the addition of new offerings such as technical accounting. Mr. Mehlman adds 30 years of experience managing, consulting to and investing in life science and healthcare companies to Danforth’s rapidly growing team.

“We’re excited to welcome Hamilton to the team, given his background in both life sciences and finance, and his expertise in advising companies ranging from seed stage to publicly traded,” said Daniel Geffken, Co-founder and Managing Director of Danforth. “In six short years, we’ve grown from a consultancy of two to a team of 50; reflecting the market need for finance and strategy professionals who understand the pace and demands of the life science and healthcare sectors. We have successfully served the well-established life science hub in Boston, and we’re expanding our network to become the go-to resource in other established and emerging life science clusters as well, such as New York, Raleigh-Durham and internationally where we can assist cross border transactions.”

“Danforth has built an enviable brand almost entirely by word of mouth, and its impressive client roster is a testament to the quality of its services,” said Mr. Mehlman. “Together with the leadership team, I look forward to building upon this success by putting the right infrastructure, personnel and programs in place to support our growth.”

Mr. Mehlman’s background in life sciences includes senior roles in corporate management, product and business development, strategic consulting and institutional investment management. He most recently led Parabase Genomics as CEO and de facto CFO, and previously held senior operating and consulting positions for such companies as Advanced Metabolic Systems, Dianon Systems and MediSense. In addition, he has 17 years of experience in institutional life science and healthcare investment at firms reaching up to $20 billion in assets, translating to extensive knowledge about deal structure, positioning and investor “hot buttons” for both public and private companies. He holds an AB from Harvard College and MBA from Harvard Business School. He also completed two years of medical school at Tufts.

About Danforth Advisors
Danforth specializes in accounting, finance support and strategy for life science companies. Our services range from execution of day-to-day finance and accounting functions to strategic CFO advisory, capital raising, financial and operational planning and analysis, and transactional support and execution for public offerings, mergers and acquisitions. Clients at all phases of the corporate life cycle can take advantage of these services on a part-time, interim or project basis, scaling as needed. Danforth was founded in 2011 and has served over 260 life science and digital health companies with our unique, modular approach. Additional information is available at